Chronic treatment with losartan (angiotensin II type 1 receptor antagonist) normalizes enhanced acetylcholineinduced coronary vasoconstriction in isolated perfused hearts of type 2 diabetic OLETF rats

Journal of Smooth Muscle Research

Volumn 45, Issue 5, 2009, Pages 197-208

  Matsumoto, Takayuki ^a   Ozawa, Yuta ^a   Taguchi, Kumiko ^a   Kobayashi, Tsuneo ^a   Kamata, Katsuo ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

ACh; Contraction; Coronary artery; Diabetes; Perfusion pressure

Indexed keywords

ACETYLCHOLINE; AMINE OXIDE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; LOSARTAN; TEMPOL;

ANIMAL; ARTICLE; CORONARY BLOOD VESSEL; DRUG EFFECT; IN VITRO STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PATHOPHYSIOLOGY; RAT; SPIN LABELING; VASOCONSTRICTION;

ACETYLCHOLINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CORONARY VESSELS; CYCLIC N-OXIDES; DIABETES MELLITUS, TYPE 2; LOSARTAN; MALE; RATS; RATS, INBRED OLETF; SPIN LABELS; VASOCONSTRICTION;

EID: 73949126945     PISSN: 09168737     EISSN: None     Source Type: Journal    
DOI: 10.1540/jsmr.45.197     Document Type: Article

References (64)

1. BARI 2D Study Group, Frye, R.L., August, P., Brooks, M.M., Hardison, R.M., Kelsey, S.F., MacGregor, J.M., Orchard, T.J., Chaitman, B.R., Genuth, S.M., Goldberg, S.H., Hlatky, M.A., Jones, T.L., Molitch, M.E., Nesto, R.W., Sako, E.Y. and Sobel, B.E. (2009). A randomized trial of therapies for type 2 diabetes and coronary artery disease. N. Engl. J. Med. 360: 2503-2515.
2. Bax, J.J., Young, L.H., Frye, R.L., Bonow, R.O., Steinberg, H.O. and Barrett, E.J.; ADA. (2007). Screening for coronary artery disease in patients with diabetes. Diabetes Care 30: 2729-2736.
3. Beckman, J.A., Creager, M.A. and Libby, P. (2002). Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287: 2570-2581.
4. Brownlee, M. (2001). Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820.
5. Cohen, R.A. (2005). Role of nitric oxide in diabetic complications. Am. J. Ther. 12: 499-502.
6. Cohn, J.N., Tognoni, G., Valsartan Heart Failure Trial Investigators (2001). A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 345: 1667-1675.
7. Dahlof, B., Devereux, R.B., Kjeldsen, S.E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., Lindholm, L.H., Nieminen, M.S., Omvik, P., Oparil, S., Wedel, H.; LIFE Study Group (2002). Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 359: 995-1003.
8. Dayanikli, F., Grambow, D., Muzik, O., Mosca, L., Rubenfire, M. and Schwaiger, M. (1994). Early detection of abnormal coronary flow reserve in asymptomatic men at high risk for coronary artery disease using positron emission tomography. Circulation 90: 808-817.
9. De Vriese, A.S., Verbeuren, T.J., Van de Voorde, J., Lameire, N.H. and Vanhoutte, P.M. (2000). Endothelial dysfunction in diabetes. Br. J. Pharmacol. 130: 963-974.
10. Durante, W., Sunahara, F.A. and Sen, A.K. (1989). Effect of diabetes on metabolic coronary dilatation in the rat. Cardiovasc. Res. 23: 40-45.
11. Egashira, K., Suzuki, S., Hirooka, Y., Kai, H., Sugimachi, M., Imaizumu, T. and Takeshita, A. (1995). Impaired endothelium-dependent vasodilation of large epicardial and resistance coronary arteries in patients with essential hypertension. Different responses to acetylcholine and substance P. Hypertension 25: 201-206.
12. Feigl, E.O. (1998). Neural control of coronary blood flow. J. Vasc. Res. 35: 85-92.
13. Grundy, S.M., Benjamin, I.J., Burke, G.L., Chait, A., Eckel, R.H., Howard, B.V., Mitch, W., Smith, S.C. Jr. and Sowers, J.R. (1999). Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100: 1134-1146.
14. Hattori, Y., Kawasaki, H., Abe, K. and Kanno, M. (1991). Superoxide dismutase recovers altered endothelium-dependent relaxation in diabetic rat aorta. Am. J. Physiol. 261: H1086-H1094.
15. Hodgson, J.M. and Marshall, J.J. (1989). Direct vasoconstriction and endothelium-dependent vasodilation. Mechanisms of acetylcholine effects on coronary flow and arterial diameter in patients with nonstenotic coronary arteries. Circulation 79: 1043-1051.
16. Hoover, D.B. and Neely, D.A. (1997). Differentiation of muscarinic receptors mediating negative chronotropic and vasoconstrictor responses to acetylcholine in isolated rat hearts. J. Pharmacol. Exp. Ther. 282: 1337-1344.
17. Jesmin, S., Hattori, Y., Sakuma, I., Mowa, C.N. and Kitabatake, A. (2002). Role of ANG II in coronary capillary angiogenesis at the insulin-resistant stage of a NIDDM rat model. Am. J. Physiol. 283: H1387-H1397.
18. Jesmin, S., Sakuma, I., Hattori, Y. and Kitabatake, A. (2003). Role of angiotensin II in altered expression of molecules responsible for coronary matrix remodeling in insulin-resistant diabetic rats. Arterioscler. Thromb. Vasc. Biol. 23: 2021-2026.
19. Kagota, S., Yamaguchi, Y., Nakamura, K. and Kunitomo, M. (2000). Altered endothelium-dependent responsiveness in the aortas and renal arteries of Otsuka Long-Evans Tokushima Fatty (OLETF) rats, a model of non-insulin-dependent diabetes mellitus. Gen. Pharmacol. 34: 201-209.
20. Kalsner, S. (1989). Cholinergic constriction in the general circulation and its role in coronary artery spasm. Circ. Res. 65: 237-257.
21. Kamata, K. and Kobayashi, T. (1996). Changes in superoxide dismutase mRNA expression by streptozotocin-induced diabetes. Br. J. Pharmacol. 119: 583-589.
22. Kamata, K., Miyata, N. and Kasuya, Y. (1989). Impairment of endothelium-dependent relaxation and changes in levels of cyclic GMP in aorta from streptozotocin-induced diabetic rats. Br. J. Pharmacol. 97: 614-618.
23. Kamata, K., Ozawa, Y., Kobayashi, T. and Matsumoto, T. (2008). Effect of long-term streptozotocin-induced diabetes on coronary vasoconstriction in isolated perfused rat heart. J. Smooth Muscle Res. 44: 177-188.
24. Kamata, K., Ozawa, Y., Kobayashi, T. and Matsumoto, T. (2009). Effect of N-epsilon(carboxymethyl)lysine on coronary vasoconstriction in isolated perfused hearts from control and streptozotocin-induced diabetic rats. J. Smooth Muscle Res. 45: 125-137.
25. Kawamura, A., Fujiwara, H., Onodera, T., Wu, D.J., Matsuda, M., Ishida, M., Takemura, G., Fujiwara, Y. and Kawai, C. (1989). Response of large and small coronary arteries of pigs to intracoronary injection of acetylcholine: angiographic and histologic analysis. Int. J. Cardiol. 25: 289-302.
26. Kawano, K., Hirashima, T., Mori, S., Saitoh, Y., Kurosumi, M. and Natori, T. (1992). Spontaneous longterm hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 41: 1422-1428.
27. Kim, S. and Iwao, H. (2000). Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol. Rev. 52: 11-34.
28. Kim, Y.K., Lee, M.S., Son, S.M., Kim, I.J., Lee, W.S., Rhim, B.Y., Hong, K.W. and Kim, C.D. (2002). Vascular NADH oxidase is involved in impaired endothelium-dependent vasodilation in OLETF rats, a model of type 2 diabetes. Diabetes 51: 522-527.
29. Kobayashi, T., Hayashi, Y., Taguchi, K., Matsumoto, T. and Kamata, K. (2006). ANG II enhances contractile responses via PI3-kinase p110 delta pathway in aortas from diabetic rats with systemic hyperinsulinemia. Am. J. Physiol. 291: H846-H853.
30. Kobayashi, T., Matsumoto, T. and Kamata, K. (2000). Mechanisms underlying the chronic pravastatin treatment-induced improvement in the impaired endothelium-dependent aortic relaxation seen in streptozotocin-induced diabetic rats. Br. J. Pharmacol. 131: 231-238.
31. Kobayashi, T., Matsumoto, T. and Kamata, K. (2005). The PI3-K/Akt pathway: roles related to alterations in vasomotor responses in diabetic models. J. Smooth Muscle Res. 41: 283-302.
32. Kobayashi, T., Taguchi, K., Yasuhiro, T., Matsumoto, T. and Kamata, K. (2004). Impairment of PI3-K/Akt pathway underlies attenuated endothelial function in aorta of type 2 diabetic mouse model. Hypertension 44: 956-962.
33. Lee, C.D., Folsom, A.R., Pankow, J.S., Brancati, F.L.; Atherosclerosis Risk in Communities (ARIC) Study Investigators (2004). Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. Circulation 109: 855-860.
34. Matsumoto, T., Kakami, M., Noguchi, E., Kobayashi, T. and Kamata, K. (2007a). Imbalance between endothelium-derived relaxing and contracting factors in mesenteric arteries from aged OLETF rats, a model of Type 2 diabetes. Am. J. Physiol. 293: H1480-H1490.
35. Matsumoto, T., Kobayashi, T. and Kamata, K. (2003a). Alterations in EDHF-type relaxation and phosphodiesterase activity in mesenteric arteries from diabetic rats. Am. J. Physiol. 285: H283-H291.
36. Matsumoto, T., Kobayashi, T. and Kamata, K. (2006a). Mechanisms underlying lysophosphatidylcholineinduced potentiation of vascular contractions in the Otsuka Long-Evans Tokushima Fatty (OLETF) rat aorta. Br. J. Pharmacol. 149: 931-941.
37. Matsumoto, T., Kobayashi, T. and Kamata, K. (2006b). Mechanisms underlying the impaired EDHF-type relaxation response in mesenteric arteries from Otsuka Long-Evans Tokushima Fatty (OLETF) Coronary effects of losartan in diabetes 207 rats. Eur. J. Pharmacol. 538: 132-140.
38. Matsumoto, T., Kobayashi, T. and Kamata, K. (2003b). Phosphodiesterases in the vascular system. J. Smooth Muscle Res. 39: 67-86.
39. Matsumoto, T., Kobayashi, T. and Kamata, K. (2008a). Relationships among ET-1, PPARgamma, oxidative stress and endothelial dysfunction in diabetic animals. J. Smooth Muscle Res. 44: 41-55.
40. Matsumoto, T., Kobayashi, T., Wachi, H., Seyama, Y. and Kamata, K. (2007b). Vascular NAD(P)H oxidase mediates endothelial dysfunction in basilar arteries from Otsuka Long-Evans Tokushima Fatty (OLETF) rats. Atherosclerosis 192: 15-24.
41. Matsumoto, T., Kobayashi, T., Wakabayashi, K. and Kamata, K. (2005). Cilostazol improves endothelium-derived hyperpolarizing factor-type relaxation in mesenteric arteries from diabetic rats. Am. J. Physiol. 289: H1933-H1940.
42. Matsumoto, T., Miyamori, K., Kobayashi, T. and Kamata, K. (2006c). Apocynin normalizes hyperreactivity to phenylephrine in mesenteric arteries from cholesterol-fed mice by improving endothelium-derived hyperpolarizing factor response. Free Radic. Biol. Med. 41: 1289-1303.
43. Matsumoto, T., Nakayama, N., Ishida, K., Kobayashi, T. and Kamata, K. (2009). Eicosapentaenoic acid improves imbalance between vasodilator and vasoconstrictor actions of endothelium-derived factors in mesenteric arteries from rats at chronic stage of type 2 diabetes. J. Pharmacol. Exp. Ther. 329: 324-334.
44. Matsumoto, T., Noguci, E., Ishida, K., Kobayashi, T., Yamada, N. and Kamata, K. (2008b). Metformin normalizes endothelial function by suppressing vasoconstrictor prostanoids in mesenteric arteries from OLETF rats, a model of type 2 diabetes. Am. J. Physiol. 295: H1165-H1176.
45. Matsumoto, T., Noguchi, E., Ishida, K., Nakayama, N., Kobayashi, T. and Kamata, K. (2008c). Cilostazol improves endothelial dysfunction by increasing endothelium-derived hyperpolarizing factor response in mesenteric arteries from Type 2 diabetic rats. Eur. J. Pharmacol. 599: 102-109.
46. Matsumoto, T., Noguchi, E., Kobayashi, T. and Kamata, K. (2007c). Mechanisms underlying the chronic pioglitazone treatment-induced improvement in the impaired endothelium-dependent relaxation seen in aortas from diabetic rats. Free Radic. Biol. Med. 42: 993-1007.
47. Matsumoto, T., Wakabayashi, K., Kobayashi, T. and Kamata, K. (2004). Diabetes-related changes in cAMP-dependent protein kinase activity and decrease in relaxation response in rat mesenteric artery. Am. J. Physiol. 287: H1064-H1071.
48. Minami, A., Ishimura, N., Harada, N., Sakamoto, S., Niwa, Y. and Nakaya, Y. (2002). Exercise training improves acetylcholine-induced endothelium-dependent hyperpolarization in type 2 diabetic rats, Otsuka Long-Evans Tokushima fatty rats. Atherosclerosis 162: 85-92.
49. Nahser, P.J.Jr., Brown, R.E., Oskarsson, H., Winniford, M.D. and Rossen, J.D. (1995). Maximal coronary flow reserve and metabolic coronary vasodilation in patients with diabetes mellitus. Circulation 91: 635-640.
50. Paul, M., Poyan Mehr, A. and Kreulz, R. (2006). Physiology of local renin-angiotensin systems. Physiol. Rev. 86: 747-803.
51. Poston, L. and Taylor, P.D. (1995). Endothelium-mediated vascular function in insulin-dependent diabetes mellitus. Clin. Sci. 88: 245-255.
52. Sakai, K. (1980). Coronary vasoconstriction by locally administered acetylcholine, carbachol and bethanechol in isolated, donor-perfused, rat hearts. Br. J. Pharmacol. 68: 625-632.
53. Sakamoto, S., Minami, K., Niwa, Y., Ohnaka, M., Nakaya, Y., Mizuno, A., Kuwajima, M. and Shima, K. (1998). Effect of exercise training and food restriction on endothelium-dependent relaxation in the Otsuka Long-Evans Tokushima Fatty rat, a model of spontaneous NIDDM. Diabetes 47: 82-86.
54. Shastri, S., Gopalakrishnan, V., Poduri, R. and Di Wang, H. (2002). Tempol selectively attenuates angiotensin II evoked vasoconstrictor responses in spontaneously hypertensive rats. J. Hypertens. 20: 1381-1391.
55. Sowers, J.R. (2004). Treatment of hypertension in patients with diabetes. Arch. Intern. Med. 164: 1850-1857.
56. Strauer, B.E. (1992). The concept of coronary flow reserve. J. Cardiovasc. Pharmacol. 19: S67-S80.
57. Strauer, B.E., Motz, W., Vogt, M. and Schwartzkopff, B. (1997). Impaired coronary flow reserve in NIDDM: a possible role for diabetic cardiopathy in humans. Diabetes 46: S119-S124.
58. Taguchi, K., Kobayashi, T., Hayashi, Y., Matsumoto, T. and Kamata, K. (2007). Enalapril improves impairment of SERCA-derived relaxation and enhancement of tyrosine nitration in diabetic rat aorta. Eur. J. Pharmacol. 556: 121-128.
59. The SOLVD Investigators (1991). Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325: 293-302.
60. Toda, N., Ayajiki, K. and Okamura, T. (2007). Interaction of endothelial nitric oxide and angiotensin in the circulation. Pharmacol. Rev. 59: 54-87.
61. Weselcouch, E.O., Baird, A.J., Sleph, P. and Grover, G.J. (1995). Inhibition of nitric oxide synthesis does not affect ischemic preconditioning in isolated perfused rat hearts. Am. J. Physiol. 268: H242-H249.
62. Yu, Y., Ohmori, K., Kondo, I., Yao, L., Noma, T., Tsuji, T., Mizushige, K. and Kohno, M. (2002). Correlation of functional and structural alterations of the coronary arteries during development of type II diabetes mellitus in rats. Cardiovasc. Res. 56: 303-311.
63. Zhang, Y. and Hoover, D.B. (2000). Signaling mechanisms for muscarinic receptor-mediated coronary vasoconstriction in isolated rat hearts. J. Pharmacol. Exp. Ther. 293: 96-106.
64. Zimmet, P., Alberti, K.G. and Shaw, J. (2001). Global and societal implications of the diabetes epidemic. Nature 414: 782-787.